2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

5912 A non-activating CD3 ligand enables targeted lipid nanoparticle delivery for in vivo CAR-T cell generation

Yiqi Li, Qiqi Zhang2, Yingjie Lu3, Liuhai Zheng4, Dongrui Wang5, He Huang, MD, PhD6
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
6 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Background

In vivo generation of chimeric antigen receptor (CAR) T cells using lipid nanoparticles (LNPs) targeting T-cell surface proteins represents a promising strategy for cancer immunotherapy. However, current CD3-targeting approaches rely primarily on agonistic anti-CD3 antibodies that activate TCR signaling, leading to activation-induced cell death (AICD), T-cell depletion, and potential systemic toxicity. Alternative strategies targeting other T-cell surface proteins are limited by heterogeneous receptor expression, disease-associated receptor downregulation, or suboptimal delivery efficiency. Thus, it is critical to design new strategies that enables efficient T cell-targeted LNP delivery without causing excessive activation.

Methods & Results

To address these challenges, we used an AI-assisted screening platform to identify a non-activating CD3-binding ligand. Further functional analysis of the extracellular domain of the candidate protein through in vitro affinity validation identified a peptide with CD3-binding potential. Its binding specificity was verified using CD3-knockout Jurkat cells and via confocal microscopy. The peptide was then conjugated into LNPs (LNP-Pep), and the efficiency of transfecting T cells was evaluated between LNP-Pep and anti-CD3 antibody-conjugated LNPs (LNP-Ab). In both in vitro (primary human T cells) and in vivo (NCG mice engrafted with primary T cells) models, LNP-Pep was able to efficiently transfect T cells while reducing apoptosis compared to LNP-Ab. As a result, LNP-Pep transfection or injection led to generating of higher numbers of functional CAR-T cells.

Mechanistically, compared with LNP-Ab, LNP-Pep-transfected primary T cells showed lower expression of activation and exhaustion markers, including CD69, CD25, PD-1, TIM-3, and LAG-3. Phospho-flow cytometry further confirmed minimal activation of early TCR signaling, with markedly reduced phosphorylation of ZAP70, LAT, and PLCγ1. Transcriptomic profiling demonstrated reduced expression of activation- and apoptosis-related programs together with enrichment of naïve/memory-associated signatures.

Functionally, LNP-Pep-transfected CAR-T cells exhibited more sustained cytotoxic activity against Nalm6 B-ALL cells compared with LNP-Ab. In human PBMC-engrafted, Nalm6 leukemia-bearing NCG mice, CD19-CAR mRNA-loaded LNP-Pep achieved superior tumor control and greater in vivo T-cell expansion than unmodified LNP and LNP-Ab. Post-killing RNA-seq further revealed enrichment of pathways associated with proliferation, stemness, and effector function, accompanied by lower expression of inflammatory cytokines, in the LNP-Pep group, supporting both improved phenotypic fitness and functional enhancement.

Conclusion

Our study identifies a novel non-activating CD3-targeted peptide LNP platform that decouples CD3-mediated targeted mRNA delivery from TCR activation. By reducing activation-induced cell death while preserving T-cell viability and memory-associated characteristics, this strategy increases the absolute number of functional CAR-T cells generated through in vivo LNP-mediated delivery, and enhances antitumor efficacy. These findings support non-activating CD3 targeting as a promising approach for more effective in vivo CAR-T cell therapy.

Yiqi Li: No relevant conflicts of interest to declare.